Tags

Type your tag names separated by a space and hit enter

[Endocrine and metabolic effects of metformin in combination with compound cyproterone acetate in women with polycystic ovarian syndrome].
Zhonghua Fu Chan Ke Za Zhi. 2003 Dec; 38(12):745-8.ZF

Abstract

OBJECTIVE

To study the endocrinologic and metabolic effects of metformin in combination with compound cyproterone acetate (CPA) on patients with polycystic ovarian syndrome (PCOS).

METHODS

A prospective study involved total 45 PCOS patients as group A and 20 non-PCOS infertility patients as control (group B). Complete baseline work-up including body mass index (BMI), waist/hip ratio (WHR), ferriman-Gallwey score (FGS), gonadotrophin, testosterone (T), sex hormone-binding globulin (SHBG), dehydroepiandrosterone sulfate (Ds), insulin (FI) and glucose tolerance test, were performed in all patients. Patients in group A were treated with CPA alone (group A1), metformin alone (group A2) or combination of CPA with metformin (group A3), respectively by randomization. At the end of 12-week therapy, subjects were re-evaluated and above parameters were measured.

RESULTS

Women in group A had significant increases in BMI, WHR, FGS, luteinizing hormone (LH), T, FI, insulin resistance, and significantly decrease in high-density lipoprotein (HDL)-C comparing with the control group (P < 0.01). No significant difference among A1, A2 and A3 was found at baseline. LH, T, free testosterone (FT) were significant decreased from (13.9 +/- 5.9) IU/L, (2.1 +/- 0.8) nmol/L and (2.8 +/- 2.3) nmol/L respectively to (5.8 +/- 2.2) IU/L, (1.2 +/- 0.4) nmol/L and (0.8 +/- 0.5) nmol/L respectively and SHBG was significant increased from (99 +/- 42) nmol/L to (187 +/- 64) nmol/L in group A3, when compared with LH, T and FT from (13.8 +/- 7.6) IU/L, (2.2 +/- 1.1) nmol/L and (2.5 +/- 1.9) nmol/L respectively to (11.8 +/- 6.5) IU/L, (1.8 +/- 0.8) nmol/L and (1.7 +/- 1.0) nmol/L respectively and SHBG from (99 +/- 40) nmol/L to (120 +/- 51) nmol/L in group A2 (P < 0.05 approximately 0.001). HDL-C were significantly increased from (1.5 +/- 0.3) mmol/L to (1.8 +/- 0.3) mmol/L in group A3 comparing with HDL-C from (1.5 +/- 0.4) mmol/L to (1.6 +/- 0.4) mmol/L in group A1 (P < 0.001).

CONCLUSIONS

The PCOS patients treated with metformin in combination with compound cyproterone acetate may be more effective in inhibiting hyperandrogen and hypersecretion of LH than metformin alone and more obvious in improving lipid profiles than CPA alone.

Authors+Show Affiliations

Ye BL
Department of Reproductive Medicine, First Affiliated Hospital, Wenzhou Medical College, Wenzhou, Zhejiang Province 325000, China.
Yang HY
No affiliation info available
Zhao JZ
No affiliation info available
Lin JJ
No affiliation info available
Lin WQ
No affiliation info available

MeSH

AdultAntineoplastic AgentsCholesterol, HDLCyproterone AcetateDehydroepiandrosteroneDrug Therapy, CombinationFemaleGonadotropinsHumansHypoglycemic AgentsInsulinLuteinizing HormoneMetforminPolycystic Ovary SyndromeProspective StudiesSex Hormone-Binding GlobulinTestosteroneTreatment Outcome

Pub Type(s)

Clinical Trial
Comparative Study
English Abstract
Journal Article
Randomized Controlled Trial

Language

chi

PubMed ID

14728846

Citation

Ye, Bi-lü, et al. "[Endocrine and Metabolic Effects of Metformin in Combination With Compound Cyproterone Acetate in Women With Polycystic Ovarian Syndrome]." Zhonghua Fu Chan Ke Za Zhi, vol. 38, no. 12, 2003, pp. 745-8.
Ye BL, Yang HY, Zhao JZ, et al. [Endocrine and metabolic effects of metformin in combination with compound cyproterone acetate in women with polycystic ovarian syndrome]. Zhonghua Fu Chan Ke Za Zhi. 2003;38(12):745-8.
Ye, B. L., Yang, H. Y., Zhao, J. Z., Lin, J. J., & Lin, W. Q. (2003). [Endocrine and metabolic effects of metformin in combination with compound cyproterone acetate in women with polycystic ovarian syndrome]. Zhonghua Fu Chan Ke Za Zhi, 38(12), 745-8.
Ye BL, et al. [Endocrine and Metabolic Effects of Metformin in Combination With Compound Cyproterone Acetate in Women With Polycystic Ovarian Syndrome]. Zhonghua Fu Chan Ke Za Zhi. 2003;38(12):745-8. PubMed PMID: 14728846.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Endocrine and metabolic effects of metformin in combination with compound cyproterone acetate in women with polycystic ovarian syndrome]. AU - Ye,Bi-lü, AU - Yang,Hai-yan, AU - Zhao,Jun-zhao, AU - Lin,Jin-ju, AU - Lin,Wen-qin, PY - 2004/1/20/pubmed PY - 2004/4/23/medline PY - 2004/1/20/entrez SP - 745 EP - 8 JF - Zhonghua fu chan ke za zhi JO - Zhonghua Fu Chan Ke Za Zhi VL - 38 IS - 12 N2 - OBJECTIVE: To study the endocrinologic and metabolic effects of metformin in combination with compound cyproterone acetate (CPA) on patients with polycystic ovarian syndrome (PCOS). METHODS: A prospective study involved total 45 PCOS patients as group A and 20 non-PCOS infertility patients as control (group B). Complete baseline work-up including body mass index (BMI), waist/hip ratio (WHR), ferriman-Gallwey score (FGS), gonadotrophin, testosterone (T), sex hormone-binding globulin (SHBG), dehydroepiandrosterone sulfate (Ds), insulin (FI) and glucose tolerance test, were performed in all patients. Patients in group A were treated with CPA alone (group A1), metformin alone (group A2) or combination of CPA with metformin (group A3), respectively by randomization. At the end of 12-week therapy, subjects were re-evaluated and above parameters were measured. RESULTS: Women in group A had significant increases in BMI, WHR, FGS, luteinizing hormone (LH), T, FI, insulin resistance, and significantly decrease in high-density lipoprotein (HDL)-C comparing with the control group (P < 0.01). No significant difference among A1, A2 and A3 was found at baseline. LH, T, free testosterone (FT) were significant decreased from (13.9 +/- 5.9) IU/L, (2.1 +/- 0.8) nmol/L and (2.8 +/- 2.3) nmol/L respectively to (5.8 +/- 2.2) IU/L, (1.2 +/- 0.4) nmol/L and (0.8 +/- 0.5) nmol/L respectively and SHBG was significant increased from (99 +/- 42) nmol/L to (187 +/- 64) nmol/L in group A3, when compared with LH, T and FT from (13.8 +/- 7.6) IU/L, (2.2 +/- 1.1) nmol/L and (2.5 +/- 1.9) nmol/L respectively to (11.8 +/- 6.5) IU/L, (1.8 +/- 0.8) nmol/L and (1.7 +/- 1.0) nmol/L respectively and SHBG from (99 +/- 40) nmol/L to (120 +/- 51) nmol/L in group A2 (P < 0.05 approximately 0.001). HDL-C were significantly increased from (1.5 +/- 0.3) mmol/L to (1.8 +/- 0.3) mmol/L in group A3 comparing with HDL-C from (1.5 +/- 0.4) mmol/L to (1.6 +/- 0.4) mmol/L in group A1 (P < 0.001). CONCLUSIONS: The PCOS patients treated with metformin in combination with compound cyproterone acetate may be more effective in inhibiting hyperandrogen and hypersecretion of LH than metformin alone and more obvious in improving lipid profiles than CPA alone. SN - 0529-567X UR - https://www.unboundmedicine.com/medline/citation/14728846/[Endocrine_and_metabolic_effects_of_metformin_in_combination_with_compound_cyproterone_acetate_in_women_with_polycystic_ovarian_syndrome]_ DB - PRIME DP - Unbound Medicine ER -